Pentasa is a prescription medication used to treat mild to moderate ulcerative colitis. Its active ingredient mesalazine delivers an anti-inflammatory effect directly to the colon lining. The drug works by inhibiting the production of prostaglandins that mediate inflammation in the gastrointestinal tract. This action reduces swelling and ulceration of the colon mucosa, helping to control disease activity. By acting locally with minimal systemic absorption, Pentasa spares surrounding tissues from excessive immunosuppression. Clinically, this leads to improved stool frequency and reduced abdominal discomfort for patients with ulcerative colitis.

Pentasa is a brand name for the anti-inflammatory medication mesalazine that targets ulcerative colitis. It works by delivering 5-aminosalicylic acid directly to the colon where it reduces inflammation. The drug penetrates the inflamed mucosa and inhibits the production of inflammatory prostaglandins. By decreasing inflammatory mediators it helps to relieve diarrhea bleeding and abdominal pain. Pentasa is formulated as a delayed-release tablet that ensures the active ingredient is released in the intestine. This targeted delivery allows the medication to act locally while minimizing systemic exposure.

Common side effects include headache and abdominal pain. Some users may experience nausea or diarrhea. Rarely, there can be joint pain or skin rash. Most symptoms are mild and temporary. The drug is not known to cause severe allergic reactions. Patient experiences vary and not all individuals report these effects.

Common side effects of Pentasa include headache. Some patients may experience abdominal pain. Nausea and vomiting can also occur. Occasionally, diarrhea or constipation may develop. Infrequent skin reactions such as rash or itching have been reported. Severe complications like intestinal strictures are rare but possible.